Shattuck Labs Q2 net loss widens to $15.2M; cash $208M; SL-325 Phase 1 positive

Shattuck Labs, Inc.

2026-Q2 EPS reported -$0.25

Q2 2026 net loss $15.2M ($0.12/sh) vs $12.5M ($0.24/sh) in Q2 2025; R&D $11.7M, G&A $4.5M.
Cash, equivalents and short-term investments $208.3M at 6/30/26, expected to fund operations into 2029.
SL-325 Phase 1: 3.7% ADA, >3-month DR3 blockade at ≥1mg/kg, favorable safety, no DR3 agonism.
RECEPTIVE-CD1 Phase 2b Crohn's starts Q3 2026: ~232 pts, primary endpoint endoscopic response at 12 wks, data 1H 2028.
SL-846 bispecific (DR3 x IL-23R) in IND-enabling tox; Phase 1 healthy volunteer trial expected 2027; poster at UEGW Oct 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.